Editor’s word: This story has been up to date with further info from a submitting with the Securities and Change Fee.
Pear Therapeutics, maker of prescription digital therapeutics, introduced in the present day that it has filed for Chapter 11 chapter and is searching for a sale of its enterprise or property.
The corporate will proceed its scaled-down operations throughout Chapter 11 because it seeks a sale, and Pear will use its accessible money to fund its operations and prices post-petition.
The Boston-based firm’s CEO Corey McCann referenced the filing on LinkedIn, stating, “In the present day is a tough day for Pear Therapeutics. We introduced that Pear voluntarily filed for Chapter 11 and can search to promote property by way of a gross sales course of. We additionally introduced a discount in power, together with me. That is actually not the end result I envisioned after I based Pear in 2013.”
In a submitting with the Securities and Exchange Commission, Pear mentioned it could lay off roughly 170 workers, almost its complete workforce. The corporate would keep a transition group of about 15 workers to proceed operations in reference to Chapter 11.
McCann stepped down as the corporate’s CEO and president. In accordance with the submitting, he’ll proceed to function a board member and supply consulting providers by way of the deliberate sale course of. Christopher D.T. Guiffre, Pear’s chief working officer and chief monetary officer, will function the corporate’s government officer.
By way of LinkedIn, McCann thanked the departing Pear workers and highlighted their accomplishment in bringing a few of the first prescription digital therapeutics to market. He famous market circumstances induced the corporate and different growth-stage companies to face challenges during the last two years.
“Here is to the way forward for digital drugs that we have labored so onerous to create,” McCann mentioned.
THE LARGER TREND
Final month, Pear announced it was exploring “strategic alternatives,” together with a doable firm sale, merger or acquisition. It employed a monetary advisor to look into actions that would “maximize shareholder worth,” together with a possible sale, M&A, divestiture of property, licensing or different strategic transactions.
With no transaction, Pear mentioned the corporate would wish to reorganize, liquidate or pursue different kinds of restructuring. In a filing with the Securities and Exchange Commission, Pear withdrew its income and working steering for fiscal 2022 and 2023. It didn’t maintain a fourth quarter and full-year earnings name.
The publicly-traded firm wasn’t resistant to the various layoffs seen all through the digital well being sector. In November, Pear mentioned it could reduce its workforce by about 59 employees, or round 22% of the corporate. In July, it let go of approximately 25 employees, making up about 9% of its workforce.
Nonetheless, final yr the corporate established quite a few partnerships to increase entry to its reSET and reSET-O choices geared toward treating substance use and opioid use dysfunction, together with collaborating with the Wisconsin Department of Health Services, Spero Health, and the California Division of Healthcare Companies. The corporate additionally introduced plans to supply its prescription digital therapeutics through telehealth providers.
Dr. Cecil Lynch provides extra particulars throughout the HIMSS23 session “How the Human Genome is Altering Precision Drugs.” It’s scheduled for Wednesday, April 19 at 11:30 a.m. – 12:30 p.m. CT at South Constructing, Degree 4, room S406 A.
Editor’s word: This story has been up to date with further info from a submitting with the Securities and Change Fee.
Pear Therapeutics, maker of prescription digital therapeutics, introduced in the present day that it has filed for Chapter 11 chapter and is searching for a sale of its enterprise or property.
The corporate will proceed its scaled-down operations throughout Chapter 11 because it seeks a sale, and Pear will use its accessible money to fund its operations and prices post-petition.
The Boston-based firm’s CEO Corey McCann referenced the filing on LinkedIn, stating, “In the present day is a tough day for Pear Therapeutics. We introduced that Pear voluntarily filed for Chapter 11 and can search to promote property by way of a gross sales course of. We additionally introduced a discount in power, together with me. That is actually not the end result I envisioned after I based Pear in 2013.”
In a submitting with the Securities and Exchange Commission, Pear mentioned it could lay off roughly 170 workers, almost its complete workforce. The corporate would keep a transition group of about 15 workers to proceed operations in reference to Chapter 11.
McCann stepped down as the corporate’s CEO and president. In accordance with the submitting, he’ll proceed to function a board member and supply consulting providers by way of the deliberate sale course of. Christopher D.T. Guiffre, Pear’s chief working officer and chief monetary officer, will function the corporate’s government officer.
By way of LinkedIn, McCann thanked the departing Pear workers and highlighted their accomplishment in bringing a few of the first prescription digital therapeutics to market. He famous market circumstances induced the corporate and different growth-stage companies to face challenges during the last two years.
“Here is to the way forward for digital drugs that we have labored so onerous to create,” McCann mentioned.
THE LARGER TREND
Final month, Pear announced it was exploring “strategic alternatives,” together with a doable firm sale, merger or acquisition. It employed a monetary advisor to look into actions that would “maximize shareholder worth,” together with a possible sale, M&A, divestiture of property, licensing or different strategic transactions.
With no transaction, Pear mentioned the corporate would wish to reorganize, liquidate or pursue different kinds of restructuring. In a filing with the Securities and Exchange Commission, Pear withdrew its income and working steering for fiscal 2022 and 2023. It didn’t maintain a fourth quarter and full-year earnings name.
The publicly-traded firm wasn’t resistant to the various layoffs seen all through the digital well being sector. In November, Pear mentioned it could reduce its workforce by about 59 employees, or round 22% of the corporate. In July, it let go of approximately 25 employees, making up about 9% of its workforce.
Nonetheless, final yr the corporate established quite a few partnerships to increase entry to its reSET and reSET-O choices geared toward treating substance use and opioid use dysfunction, together with collaborating with the Wisconsin Department of Health Services, Spero Health, and the California Division of Healthcare Companies. The corporate additionally introduced plans to supply its prescription digital therapeutics through telehealth providers.
Dr. Cecil Lynch provides extra particulars throughout the HIMSS23 session “How the Human Genome is Altering Precision Drugs.” It’s scheduled for Wednesday, April 19 at 11:30 a.m. – 12:30 p.m. CT at South Constructing, Degree 4, room S406 A.
Editor’s word: This story has been up to date with further info from a submitting with the Securities and Change Fee.
Pear Therapeutics, maker of prescription digital therapeutics, introduced in the present day that it has filed for Chapter 11 chapter and is searching for a sale of its enterprise or property.
The corporate will proceed its scaled-down operations throughout Chapter 11 because it seeks a sale, and Pear will use its accessible money to fund its operations and prices post-petition.
The Boston-based firm’s CEO Corey McCann referenced the filing on LinkedIn, stating, “In the present day is a tough day for Pear Therapeutics. We introduced that Pear voluntarily filed for Chapter 11 and can search to promote property by way of a gross sales course of. We additionally introduced a discount in power, together with me. That is actually not the end result I envisioned after I based Pear in 2013.”
In a submitting with the Securities and Exchange Commission, Pear mentioned it could lay off roughly 170 workers, almost its complete workforce. The corporate would keep a transition group of about 15 workers to proceed operations in reference to Chapter 11.
McCann stepped down as the corporate’s CEO and president. In accordance with the submitting, he’ll proceed to function a board member and supply consulting providers by way of the deliberate sale course of. Christopher D.T. Guiffre, Pear’s chief working officer and chief monetary officer, will function the corporate’s government officer.
By way of LinkedIn, McCann thanked the departing Pear workers and highlighted their accomplishment in bringing a few of the first prescription digital therapeutics to market. He famous market circumstances induced the corporate and different growth-stage companies to face challenges during the last two years.
“Here is to the way forward for digital drugs that we have labored so onerous to create,” McCann mentioned.
THE LARGER TREND
Final month, Pear announced it was exploring “strategic alternatives,” together with a doable firm sale, merger or acquisition. It employed a monetary advisor to look into actions that would “maximize shareholder worth,” together with a possible sale, M&A, divestiture of property, licensing or different strategic transactions.
With no transaction, Pear mentioned the corporate would wish to reorganize, liquidate or pursue different kinds of restructuring. In a filing with the Securities and Exchange Commission, Pear withdrew its income and working steering for fiscal 2022 and 2023. It didn’t maintain a fourth quarter and full-year earnings name.
The publicly-traded firm wasn’t resistant to the various layoffs seen all through the digital well being sector. In November, Pear mentioned it could reduce its workforce by about 59 employees, or round 22% of the corporate. In July, it let go of approximately 25 employees, making up about 9% of its workforce.
Nonetheless, final yr the corporate established quite a few partnerships to increase entry to its reSET and reSET-O choices geared toward treating substance use and opioid use dysfunction, together with collaborating with the Wisconsin Department of Health Services, Spero Health, and the California Division of Healthcare Companies. The corporate additionally introduced plans to supply its prescription digital therapeutics through telehealth providers.
Dr. Cecil Lynch provides extra particulars throughout the HIMSS23 session “How the Human Genome is Altering Precision Drugs.” It’s scheduled for Wednesday, April 19 at 11:30 a.m. – 12:30 p.m. CT at South Constructing, Degree 4, room S406 A.
Editor’s word: This story has been up to date with further info from a submitting with the Securities and Change Fee.
Pear Therapeutics, maker of prescription digital therapeutics, introduced in the present day that it has filed for Chapter 11 chapter and is searching for a sale of its enterprise or property.
The corporate will proceed its scaled-down operations throughout Chapter 11 because it seeks a sale, and Pear will use its accessible money to fund its operations and prices post-petition.
The Boston-based firm’s CEO Corey McCann referenced the filing on LinkedIn, stating, “In the present day is a tough day for Pear Therapeutics. We introduced that Pear voluntarily filed for Chapter 11 and can search to promote property by way of a gross sales course of. We additionally introduced a discount in power, together with me. That is actually not the end result I envisioned after I based Pear in 2013.”
In a submitting with the Securities and Exchange Commission, Pear mentioned it could lay off roughly 170 workers, almost its complete workforce. The corporate would keep a transition group of about 15 workers to proceed operations in reference to Chapter 11.
McCann stepped down as the corporate’s CEO and president. In accordance with the submitting, he’ll proceed to function a board member and supply consulting providers by way of the deliberate sale course of. Christopher D.T. Guiffre, Pear’s chief working officer and chief monetary officer, will function the corporate’s government officer.
By way of LinkedIn, McCann thanked the departing Pear workers and highlighted their accomplishment in bringing a few of the first prescription digital therapeutics to market. He famous market circumstances induced the corporate and different growth-stage companies to face challenges during the last two years.
“Here is to the way forward for digital drugs that we have labored so onerous to create,” McCann mentioned.
THE LARGER TREND
Final month, Pear announced it was exploring “strategic alternatives,” together with a doable firm sale, merger or acquisition. It employed a monetary advisor to look into actions that would “maximize shareholder worth,” together with a possible sale, M&A, divestiture of property, licensing or different strategic transactions.
With no transaction, Pear mentioned the corporate would wish to reorganize, liquidate or pursue different kinds of restructuring. In a filing with the Securities and Exchange Commission, Pear withdrew its income and working steering for fiscal 2022 and 2023. It didn’t maintain a fourth quarter and full-year earnings name.
The publicly-traded firm wasn’t resistant to the various layoffs seen all through the digital well being sector. In November, Pear mentioned it could reduce its workforce by about 59 employees, or round 22% of the corporate. In July, it let go of approximately 25 employees, making up about 9% of its workforce.
Nonetheless, final yr the corporate established quite a few partnerships to increase entry to its reSET and reSET-O choices geared toward treating substance use and opioid use dysfunction, together with collaborating with the Wisconsin Department of Health Services, Spero Health, and the California Division of Healthcare Companies. The corporate additionally introduced plans to supply its prescription digital therapeutics through telehealth providers.
Dr. Cecil Lynch provides extra particulars throughout the HIMSS23 session “How the Human Genome is Altering Precision Drugs.” It’s scheduled for Wednesday, April 19 at 11:30 a.m. – 12:30 p.m. CT at South Constructing, Degree 4, room S406 A.
Editor’s word: This story has been up to date with further info from a submitting with the Securities and Change Fee.
Pear Therapeutics, maker of prescription digital therapeutics, introduced in the present day that it has filed for Chapter 11 chapter and is searching for a sale of its enterprise or property.
The corporate will proceed its scaled-down operations throughout Chapter 11 because it seeks a sale, and Pear will use its accessible money to fund its operations and prices post-petition.
The Boston-based firm’s CEO Corey McCann referenced the filing on LinkedIn, stating, “In the present day is a tough day for Pear Therapeutics. We introduced that Pear voluntarily filed for Chapter 11 and can search to promote property by way of a gross sales course of. We additionally introduced a discount in power, together with me. That is actually not the end result I envisioned after I based Pear in 2013.”
In a submitting with the Securities and Exchange Commission, Pear mentioned it could lay off roughly 170 workers, almost its complete workforce. The corporate would keep a transition group of about 15 workers to proceed operations in reference to Chapter 11.
McCann stepped down as the corporate’s CEO and president. In accordance with the submitting, he’ll proceed to function a board member and supply consulting providers by way of the deliberate sale course of. Christopher D.T. Guiffre, Pear’s chief working officer and chief monetary officer, will function the corporate’s government officer.
By way of LinkedIn, McCann thanked the departing Pear workers and highlighted their accomplishment in bringing a few of the first prescription digital therapeutics to market. He famous market circumstances induced the corporate and different growth-stage companies to face challenges during the last two years.
“Here is to the way forward for digital drugs that we have labored so onerous to create,” McCann mentioned.
THE LARGER TREND
Final month, Pear announced it was exploring “strategic alternatives,” together with a doable firm sale, merger or acquisition. It employed a monetary advisor to look into actions that would “maximize shareholder worth,” together with a possible sale, M&A, divestiture of property, licensing or different strategic transactions.
With no transaction, Pear mentioned the corporate would wish to reorganize, liquidate or pursue different kinds of restructuring. In a filing with the Securities and Exchange Commission, Pear withdrew its income and working steering for fiscal 2022 and 2023. It didn’t maintain a fourth quarter and full-year earnings name.
The publicly-traded firm wasn’t resistant to the various layoffs seen all through the digital well being sector. In November, Pear mentioned it could reduce its workforce by about 59 employees, or round 22% of the corporate. In July, it let go of approximately 25 employees, making up about 9% of its workforce.
Nonetheless, final yr the corporate established quite a few partnerships to increase entry to its reSET and reSET-O choices geared toward treating substance use and opioid use dysfunction, together with collaborating with the Wisconsin Department of Health Services, Spero Health, and the California Division of Healthcare Companies. The corporate additionally introduced plans to supply its prescription digital therapeutics through telehealth providers.
Dr. Cecil Lynch provides extra particulars throughout the HIMSS23 session “How the Human Genome is Altering Precision Drugs.” It’s scheduled for Wednesday, April 19 at 11:30 a.m. – 12:30 p.m. CT at South Constructing, Degree 4, room S406 A.
Editor’s word: This story has been up to date with further info from a submitting with the Securities and Change Fee.
Pear Therapeutics, maker of prescription digital therapeutics, introduced in the present day that it has filed for Chapter 11 chapter and is searching for a sale of its enterprise or property.
The corporate will proceed its scaled-down operations throughout Chapter 11 because it seeks a sale, and Pear will use its accessible money to fund its operations and prices post-petition.
The Boston-based firm’s CEO Corey McCann referenced the filing on LinkedIn, stating, “In the present day is a tough day for Pear Therapeutics. We introduced that Pear voluntarily filed for Chapter 11 and can search to promote property by way of a gross sales course of. We additionally introduced a discount in power, together with me. That is actually not the end result I envisioned after I based Pear in 2013.”
In a submitting with the Securities and Exchange Commission, Pear mentioned it could lay off roughly 170 workers, almost its complete workforce. The corporate would keep a transition group of about 15 workers to proceed operations in reference to Chapter 11.
McCann stepped down as the corporate’s CEO and president. In accordance with the submitting, he’ll proceed to function a board member and supply consulting providers by way of the deliberate sale course of. Christopher D.T. Guiffre, Pear’s chief working officer and chief monetary officer, will function the corporate’s government officer.
By way of LinkedIn, McCann thanked the departing Pear workers and highlighted their accomplishment in bringing a few of the first prescription digital therapeutics to market. He famous market circumstances induced the corporate and different growth-stage companies to face challenges during the last two years.
“Here is to the way forward for digital drugs that we have labored so onerous to create,” McCann mentioned.
THE LARGER TREND
Final month, Pear announced it was exploring “strategic alternatives,” together with a doable firm sale, merger or acquisition. It employed a monetary advisor to look into actions that would “maximize shareholder worth,” together with a possible sale, M&A, divestiture of property, licensing or different strategic transactions.
With no transaction, Pear mentioned the corporate would wish to reorganize, liquidate or pursue different kinds of restructuring. In a filing with the Securities and Exchange Commission, Pear withdrew its income and working steering for fiscal 2022 and 2023. It didn’t maintain a fourth quarter and full-year earnings name.
The publicly-traded firm wasn’t resistant to the various layoffs seen all through the digital well being sector. In November, Pear mentioned it could reduce its workforce by about 59 employees, or round 22% of the corporate. In July, it let go of approximately 25 employees, making up about 9% of its workforce.
Nonetheless, final yr the corporate established quite a few partnerships to increase entry to its reSET and reSET-O choices geared toward treating substance use and opioid use dysfunction, together with collaborating with the Wisconsin Department of Health Services, Spero Health, and the California Division of Healthcare Companies. The corporate additionally introduced plans to supply its prescription digital therapeutics through telehealth providers.
Dr. Cecil Lynch provides extra particulars throughout the HIMSS23 session “How the Human Genome is Altering Precision Drugs.” It’s scheduled for Wednesday, April 19 at 11:30 a.m. – 12:30 p.m. CT at South Constructing, Degree 4, room S406 A.
Editor’s word: This story has been up to date with further info from a submitting with the Securities and Change Fee.
Pear Therapeutics, maker of prescription digital therapeutics, introduced in the present day that it has filed for Chapter 11 chapter and is searching for a sale of its enterprise or property.
The corporate will proceed its scaled-down operations throughout Chapter 11 because it seeks a sale, and Pear will use its accessible money to fund its operations and prices post-petition.
The Boston-based firm’s CEO Corey McCann referenced the filing on LinkedIn, stating, “In the present day is a tough day for Pear Therapeutics. We introduced that Pear voluntarily filed for Chapter 11 and can search to promote property by way of a gross sales course of. We additionally introduced a discount in power, together with me. That is actually not the end result I envisioned after I based Pear in 2013.”
In a submitting with the Securities and Exchange Commission, Pear mentioned it could lay off roughly 170 workers, almost its complete workforce. The corporate would keep a transition group of about 15 workers to proceed operations in reference to Chapter 11.
McCann stepped down as the corporate’s CEO and president. In accordance with the submitting, he’ll proceed to function a board member and supply consulting providers by way of the deliberate sale course of. Christopher D.T. Guiffre, Pear’s chief working officer and chief monetary officer, will function the corporate’s government officer.
By way of LinkedIn, McCann thanked the departing Pear workers and highlighted their accomplishment in bringing a few of the first prescription digital therapeutics to market. He famous market circumstances induced the corporate and different growth-stage companies to face challenges during the last two years.
“Here is to the way forward for digital drugs that we have labored so onerous to create,” McCann mentioned.
THE LARGER TREND
Final month, Pear announced it was exploring “strategic alternatives,” together with a doable firm sale, merger or acquisition. It employed a monetary advisor to look into actions that would “maximize shareholder worth,” together with a possible sale, M&A, divestiture of property, licensing or different strategic transactions.
With no transaction, Pear mentioned the corporate would wish to reorganize, liquidate or pursue different kinds of restructuring. In a filing with the Securities and Exchange Commission, Pear withdrew its income and working steering for fiscal 2022 and 2023. It didn’t maintain a fourth quarter and full-year earnings name.
The publicly-traded firm wasn’t resistant to the various layoffs seen all through the digital well being sector. In November, Pear mentioned it could reduce its workforce by about 59 employees, or round 22% of the corporate. In July, it let go of approximately 25 employees, making up about 9% of its workforce.
Nonetheless, final yr the corporate established quite a few partnerships to increase entry to its reSET and reSET-O choices geared toward treating substance use and opioid use dysfunction, together with collaborating with the Wisconsin Department of Health Services, Spero Health, and the California Division of Healthcare Companies. The corporate additionally introduced plans to supply its prescription digital therapeutics through telehealth providers.
Dr. Cecil Lynch provides extra particulars throughout the HIMSS23 session “How the Human Genome is Altering Precision Drugs.” It’s scheduled for Wednesday, April 19 at 11:30 a.m. – 12:30 p.m. CT at South Constructing, Degree 4, room S406 A.
Editor’s word: This story has been up to date with further info from a submitting with the Securities and Change Fee.
Pear Therapeutics, maker of prescription digital therapeutics, introduced in the present day that it has filed for Chapter 11 chapter and is searching for a sale of its enterprise or property.
The corporate will proceed its scaled-down operations throughout Chapter 11 because it seeks a sale, and Pear will use its accessible money to fund its operations and prices post-petition.
The Boston-based firm’s CEO Corey McCann referenced the filing on LinkedIn, stating, “In the present day is a tough day for Pear Therapeutics. We introduced that Pear voluntarily filed for Chapter 11 and can search to promote property by way of a gross sales course of. We additionally introduced a discount in power, together with me. That is actually not the end result I envisioned after I based Pear in 2013.”
In a submitting with the Securities and Exchange Commission, Pear mentioned it could lay off roughly 170 workers, almost its complete workforce. The corporate would keep a transition group of about 15 workers to proceed operations in reference to Chapter 11.
McCann stepped down as the corporate’s CEO and president. In accordance with the submitting, he’ll proceed to function a board member and supply consulting providers by way of the deliberate sale course of. Christopher D.T. Guiffre, Pear’s chief working officer and chief monetary officer, will function the corporate’s government officer.
By way of LinkedIn, McCann thanked the departing Pear workers and highlighted their accomplishment in bringing a few of the first prescription digital therapeutics to market. He famous market circumstances induced the corporate and different growth-stage companies to face challenges during the last two years.
“Here is to the way forward for digital drugs that we have labored so onerous to create,” McCann mentioned.
THE LARGER TREND
Final month, Pear announced it was exploring “strategic alternatives,” together with a doable firm sale, merger or acquisition. It employed a monetary advisor to look into actions that would “maximize shareholder worth,” together with a possible sale, M&A, divestiture of property, licensing or different strategic transactions.
With no transaction, Pear mentioned the corporate would wish to reorganize, liquidate or pursue different kinds of restructuring. In a filing with the Securities and Exchange Commission, Pear withdrew its income and working steering for fiscal 2022 and 2023. It didn’t maintain a fourth quarter and full-year earnings name.
The publicly-traded firm wasn’t resistant to the various layoffs seen all through the digital well being sector. In November, Pear mentioned it could reduce its workforce by about 59 employees, or round 22% of the corporate. In July, it let go of approximately 25 employees, making up about 9% of its workforce.
Nonetheless, final yr the corporate established quite a few partnerships to increase entry to its reSET and reSET-O choices geared toward treating substance use and opioid use dysfunction, together with collaborating with the Wisconsin Department of Health Services, Spero Health, and the California Division of Healthcare Companies. The corporate additionally introduced plans to supply its prescription digital therapeutics through telehealth providers.
Dr. Cecil Lynch provides extra particulars throughout the HIMSS23 session “How the Human Genome is Altering Precision Drugs.” It’s scheduled for Wednesday, April 19 at 11:30 a.m. – 12:30 p.m. CT at South Constructing, Degree 4, room S406 A.
Editor’s word: This story has been up to date with further info from a submitting with the Securities and Change Fee.
Pear Therapeutics, maker of prescription digital therapeutics, introduced in the present day that it has filed for Chapter 11 chapter and is searching for a sale of its enterprise or property.
The corporate will proceed its scaled-down operations throughout Chapter 11 because it seeks a sale, and Pear will use its accessible money to fund its operations and prices post-petition.
The Boston-based firm’s CEO Corey McCann referenced the filing on LinkedIn, stating, “In the present day is a tough day for Pear Therapeutics. We introduced that Pear voluntarily filed for Chapter 11 and can search to promote property by way of a gross sales course of. We additionally introduced a discount in power, together with me. That is actually not the end result I envisioned after I based Pear in 2013.”
In a submitting with the Securities and Exchange Commission, Pear mentioned it could lay off roughly 170 workers, almost its complete workforce. The corporate would keep a transition group of about 15 workers to proceed operations in reference to Chapter 11.
McCann stepped down as the corporate’s CEO and president. In accordance with the submitting, he’ll proceed to function a board member and supply consulting providers by way of the deliberate sale course of. Christopher D.T. Guiffre, Pear’s chief working officer and chief monetary officer, will function the corporate’s government officer.
By way of LinkedIn, McCann thanked the departing Pear workers and highlighted their accomplishment in bringing a few of the first prescription digital therapeutics to market. He famous market circumstances induced the corporate and different growth-stage companies to face challenges during the last two years.
“Here is to the way forward for digital drugs that we have labored so onerous to create,” McCann mentioned.
THE LARGER TREND
Final month, Pear announced it was exploring “strategic alternatives,” together with a doable firm sale, merger or acquisition. It employed a monetary advisor to look into actions that would “maximize shareholder worth,” together with a possible sale, M&A, divestiture of property, licensing or different strategic transactions.
With no transaction, Pear mentioned the corporate would wish to reorganize, liquidate or pursue different kinds of restructuring. In a filing with the Securities and Exchange Commission, Pear withdrew its income and working steering for fiscal 2022 and 2023. It didn’t maintain a fourth quarter and full-year earnings name.
The publicly-traded firm wasn’t resistant to the various layoffs seen all through the digital well being sector. In November, Pear mentioned it could reduce its workforce by about 59 employees, or round 22% of the corporate. In July, it let go of approximately 25 employees, making up about 9% of its workforce.
Nonetheless, final yr the corporate established quite a few partnerships to increase entry to its reSET and reSET-O choices geared toward treating substance use and opioid use dysfunction, together with collaborating with the Wisconsin Department of Health Services, Spero Health, and the California Division of Healthcare Companies. The corporate additionally introduced plans to supply its prescription digital therapeutics through telehealth providers.
Dr. Cecil Lynch provides extra particulars throughout the HIMSS23 session “How the Human Genome is Altering Precision Drugs.” It’s scheduled for Wednesday, April 19 at 11:30 a.m. – 12:30 p.m. CT at South Constructing, Degree 4, room S406 A.
Editor’s word: This story has been up to date with further info from a submitting with the Securities and Change Fee.
Pear Therapeutics, maker of prescription digital therapeutics, introduced in the present day that it has filed for Chapter 11 chapter and is searching for a sale of its enterprise or property.
The corporate will proceed its scaled-down operations throughout Chapter 11 because it seeks a sale, and Pear will use its accessible money to fund its operations and prices post-petition.
The Boston-based firm’s CEO Corey McCann referenced the filing on LinkedIn, stating, “In the present day is a tough day for Pear Therapeutics. We introduced that Pear voluntarily filed for Chapter 11 and can search to promote property by way of a gross sales course of. We additionally introduced a discount in power, together with me. That is actually not the end result I envisioned after I based Pear in 2013.”
In a submitting with the Securities and Exchange Commission, Pear mentioned it could lay off roughly 170 workers, almost its complete workforce. The corporate would keep a transition group of about 15 workers to proceed operations in reference to Chapter 11.
McCann stepped down as the corporate’s CEO and president. In accordance with the submitting, he’ll proceed to function a board member and supply consulting providers by way of the deliberate sale course of. Christopher D.T. Guiffre, Pear’s chief working officer and chief monetary officer, will function the corporate’s government officer.
By way of LinkedIn, McCann thanked the departing Pear workers and highlighted their accomplishment in bringing a few of the first prescription digital therapeutics to market. He famous market circumstances induced the corporate and different growth-stage companies to face challenges during the last two years.
“Here is to the way forward for digital drugs that we have labored so onerous to create,” McCann mentioned.
THE LARGER TREND
Final month, Pear announced it was exploring “strategic alternatives,” together with a doable firm sale, merger or acquisition. It employed a monetary advisor to look into actions that would “maximize shareholder worth,” together with a possible sale, M&A, divestiture of property, licensing or different strategic transactions.
With no transaction, Pear mentioned the corporate would wish to reorganize, liquidate or pursue different kinds of restructuring. In a filing with the Securities and Exchange Commission, Pear withdrew its income and working steering for fiscal 2022 and 2023. It didn’t maintain a fourth quarter and full-year earnings name.
The publicly-traded firm wasn’t resistant to the various layoffs seen all through the digital well being sector. In November, Pear mentioned it could reduce its workforce by about 59 employees, or round 22% of the corporate. In July, it let go of approximately 25 employees, making up about 9% of its workforce.
Nonetheless, final yr the corporate established quite a few partnerships to increase entry to its reSET and reSET-O choices geared toward treating substance use and opioid use dysfunction, together with collaborating with the Wisconsin Department of Health Services, Spero Health, and the California Division of Healthcare Companies. The corporate additionally introduced plans to supply its prescription digital therapeutics through telehealth providers.
Dr. Cecil Lynch provides extra particulars throughout the HIMSS23 session “How the Human Genome is Altering Precision Drugs.” It’s scheduled for Wednesday, April 19 at 11:30 a.m. – 12:30 p.m. CT at South Constructing, Degree 4, room S406 A.
Editor’s word: This story has been up to date with further info from a submitting with the Securities and Change Fee.
Pear Therapeutics, maker of prescription digital therapeutics, introduced in the present day that it has filed for Chapter 11 chapter and is searching for a sale of its enterprise or property.
The corporate will proceed its scaled-down operations throughout Chapter 11 because it seeks a sale, and Pear will use its accessible money to fund its operations and prices post-petition.
The Boston-based firm’s CEO Corey McCann referenced the filing on LinkedIn, stating, “In the present day is a tough day for Pear Therapeutics. We introduced that Pear voluntarily filed for Chapter 11 and can search to promote property by way of a gross sales course of. We additionally introduced a discount in power, together with me. That is actually not the end result I envisioned after I based Pear in 2013.”
In a submitting with the Securities and Exchange Commission, Pear mentioned it could lay off roughly 170 workers, almost its complete workforce. The corporate would keep a transition group of about 15 workers to proceed operations in reference to Chapter 11.
McCann stepped down as the corporate’s CEO and president. In accordance with the submitting, he’ll proceed to function a board member and supply consulting providers by way of the deliberate sale course of. Christopher D.T. Guiffre, Pear’s chief working officer and chief monetary officer, will function the corporate’s government officer.
By way of LinkedIn, McCann thanked the departing Pear workers and highlighted their accomplishment in bringing a few of the first prescription digital therapeutics to market. He famous market circumstances induced the corporate and different growth-stage companies to face challenges during the last two years.
“Here is to the way forward for digital drugs that we have labored so onerous to create,” McCann mentioned.
THE LARGER TREND
Final month, Pear announced it was exploring “strategic alternatives,” together with a doable firm sale, merger or acquisition. It employed a monetary advisor to look into actions that would “maximize shareholder worth,” together with a possible sale, M&A, divestiture of property, licensing or different strategic transactions.
With no transaction, Pear mentioned the corporate would wish to reorganize, liquidate or pursue different kinds of restructuring. In a filing with the Securities and Exchange Commission, Pear withdrew its income and working steering for fiscal 2022 and 2023. It didn’t maintain a fourth quarter and full-year earnings name.
The publicly-traded firm wasn’t resistant to the various layoffs seen all through the digital well being sector. In November, Pear mentioned it could reduce its workforce by about 59 employees, or round 22% of the corporate. In July, it let go of approximately 25 employees, making up about 9% of its workforce.
Nonetheless, final yr the corporate established quite a few partnerships to increase entry to its reSET and reSET-O choices geared toward treating substance use and opioid use dysfunction, together with collaborating with the Wisconsin Department of Health Services, Spero Health, and the California Division of Healthcare Companies. The corporate additionally introduced plans to supply its prescription digital therapeutics through telehealth providers.
Dr. Cecil Lynch provides extra particulars throughout the HIMSS23 session “How the Human Genome is Altering Precision Drugs.” It’s scheduled for Wednesday, April 19 at 11:30 a.m. – 12:30 p.m. CT at South Constructing, Degree 4, room S406 A.
Editor’s word: This story has been up to date with further info from a submitting with the Securities and Change Fee.
Pear Therapeutics, maker of prescription digital therapeutics, introduced in the present day that it has filed for Chapter 11 chapter and is searching for a sale of its enterprise or property.
The corporate will proceed its scaled-down operations throughout Chapter 11 because it seeks a sale, and Pear will use its accessible money to fund its operations and prices post-petition.
The Boston-based firm’s CEO Corey McCann referenced the filing on LinkedIn, stating, “In the present day is a tough day for Pear Therapeutics. We introduced that Pear voluntarily filed for Chapter 11 and can search to promote property by way of a gross sales course of. We additionally introduced a discount in power, together with me. That is actually not the end result I envisioned after I based Pear in 2013.”
In a submitting with the Securities and Exchange Commission, Pear mentioned it could lay off roughly 170 workers, almost its complete workforce. The corporate would keep a transition group of about 15 workers to proceed operations in reference to Chapter 11.
McCann stepped down as the corporate’s CEO and president. In accordance with the submitting, he’ll proceed to function a board member and supply consulting providers by way of the deliberate sale course of. Christopher D.T. Guiffre, Pear’s chief working officer and chief monetary officer, will function the corporate’s government officer.
By way of LinkedIn, McCann thanked the departing Pear workers and highlighted their accomplishment in bringing a few of the first prescription digital therapeutics to market. He famous market circumstances induced the corporate and different growth-stage companies to face challenges during the last two years.
“Here is to the way forward for digital drugs that we have labored so onerous to create,” McCann mentioned.
THE LARGER TREND
Final month, Pear announced it was exploring “strategic alternatives,” together with a doable firm sale, merger or acquisition. It employed a monetary advisor to look into actions that would “maximize shareholder worth,” together with a possible sale, M&A, divestiture of property, licensing or different strategic transactions.
With no transaction, Pear mentioned the corporate would wish to reorganize, liquidate or pursue different kinds of restructuring. In a filing with the Securities and Exchange Commission, Pear withdrew its income and working steering for fiscal 2022 and 2023. It didn’t maintain a fourth quarter and full-year earnings name.
The publicly-traded firm wasn’t resistant to the various layoffs seen all through the digital well being sector. In November, Pear mentioned it could reduce its workforce by about 59 employees, or round 22% of the corporate. In July, it let go of approximately 25 employees, making up about 9% of its workforce.
Nonetheless, final yr the corporate established quite a few partnerships to increase entry to its reSET and reSET-O choices geared toward treating substance use and opioid use dysfunction, together with collaborating with the Wisconsin Department of Health Services, Spero Health, and the California Division of Healthcare Companies. The corporate additionally introduced plans to supply its prescription digital therapeutics through telehealth providers.
Dr. Cecil Lynch provides extra particulars throughout the HIMSS23 session “How the Human Genome is Altering Precision Drugs.” It’s scheduled for Wednesday, April 19 at 11:30 a.m. – 12:30 p.m. CT at South Constructing, Degree 4, room S406 A.
Editor’s word: This story has been up to date with further info from a submitting with the Securities and Change Fee.
Pear Therapeutics, maker of prescription digital therapeutics, introduced in the present day that it has filed for Chapter 11 chapter and is searching for a sale of its enterprise or property.
The corporate will proceed its scaled-down operations throughout Chapter 11 because it seeks a sale, and Pear will use its accessible money to fund its operations and prices post-petition.
The Boston-based firm’s CEO Corey McCann referenced the filing on LinkedIn, stating, “In the present day is a tough day for Pear Therapeutics. We introduced that Pear voluntarily filed for Chapter 11 and can search to promote property by way of a gross sales course of. We additionally introduced a discount in power, together with me. That is actually not the end result I envisioned after I based Pear in 2013.”
In a submitting with the Securities and Exchange Commission, Pear mentioned it could lay off roughly 170 workers, almost its complete workforce. The corporate would keep a transition group of about 15 workers to proceed operations in reference to Chapter 11.
McCann stepped down as the corporate’s CEO and president. In accordance with the submitting, he’ll proceed to function a board member and supply consulting providers by way of the deliberate sale course of. Christopher D.T. Guiffre, Pear’s chief working officer and chief monetary officer, will function the corporate’s government officer.
By way of LinkedIn, McCann thanked the departing Pear workers and highlighted their accomplishment in bringing a few of the first prescription digital therapeutics to market. He famous market circumstances induced the corporate and different growth-stage companies to face challenges during the last two years.
“Here is to the way forward for digital drugs that we have labored so onerous to create,” McCann mentioned.
THE LARGER TREND
Final month, Pear announced it was exploring “strategic alternatives,” together with a doable firm sale, merger or acquisition. It employed a monetary advisor to look into actions that would “maximize shareholder worth,” together with a possible sale, M&A, divestiture of property, licensing or different strategic transactions.
With no transaction, Pear mentioned the corporate would wish to reorganize, liquidate or pursue different kinds of restructuring. In a filing with the Securities and Exchange Commission, Pear withdrew its income and working steering for fiscal 2022 and 2023. It didn’t maintain a fourth quarter and full-year earnings name.
The publicly-traded firm wasn’t resistant to the various layoffs seen all through the digital well being sector. In November, Pear mentioned it could reduce its workforce by about 59 employees, or round 22% of the corporate. In July, it let go of approximately 25 employees, making up about 9% of its workforce.
Nonetheless, final yr the corporate established quite a few partnerships to increase entry to its reSET and reSET-O choices geared toward treating substance use and opioid use dysfunction, together with collaborating with the Wisconsin Department of Health Services, Spero Health, and the California Division of Healthcare Companies. The corporate additionally introduced plans to supply its prescription digital therapeutics through telehealth providers.
Dr. Cecil Lynch provides extra particulars throughout the HIMSS23 session “How the Human Genome is Altering Precision Drugs.” It’s scheduled for Wednesday, April 19 at 11:30 a.m. – 12:30 p.m. CT at South Constructing, Degree 4, room S406 A.
Editor’s word: This story has been up to date with further info from a submitting with the Securities and Change Fee.
Pear Therapeutics, maker of prescription digital therapeutics, introduced in the present day that it has filed for Chapter 11 chapter and is searching for a sale of its enterprise or property.
The corporate will proceed its scaled-down operations throughout Chapter 11 because it seeks a sale, and Pear will use its accessible money to fund its operations and prices post-petition.
The Boston-based firm’s CEO Corey McCann referenced the filing on LinkedIn, stating, “In the present day is a tough day for Pear Therapeutics. We introduced that Pear voluntarily filed for Chapter 11 and can search to promote property by way of a gross sales course of. We additionally introduced a discount in power, together with me. That is actually not the end result I envisioned after I based Pear in 2013.”
In a submitting with the Securities and Exchange Commission, Pear mentioned it could lay off roughly 170 workers, almost its complete workforce. The corporate would keep a transition group of about 15 workers to proceed operations in reference to Chapter 11.
McCann stepped down as the corporate’s CEO and president. In accordance with the submitting, he’ll proceed to function a board member and supply consulting providers by way of the deliberate sale course of. Christopher D.T. Guiffre, Pear’s chief working officer and chief monetary officer, will function the corporate’s government officer.
By way of LinkedIn, McCann thanked the departing Pear workers and highlighted their accomplishment in bringing a few of the first prescription digital therapeutics to market. He famous market circumstances induced the corporate and different growth-stage companies to face challenges during the last two years.
“Here is to the way forward for digital drugs that we have labored so onerous to create,” McCann mentioned.
THE LARGER TREND
Final month, Pear announced it was exploring “strategic alternatives,” together with a doable firm sale, merger or acquisition. It employed a monetary advisor to look into actions that would “maximize shareholder worth,” together with a possible sale, M&A, divestiture of property, licensing or different strategic transactions.
With no transaction, Pear mentioned the corporate would wish to reorganize, liquidate or pursue different kinds of restructuring. In a filing with the Securities and Exchange Commission, Pear withdrew its income and working steering for fiscal 2022 and 2023. It didn’t maintain a fourth quarter and full-year earnings name.
The publicly-traded firm wasn’t resistant to the various layoffs seen all through the digital well being sector. In November, Pear mentioned it could reduce its workforce by about 59 employees, or round 22% of the corporate. In July, it let go of approximately 25 employees, making up about 9% of its workforce.
Nonetheless, final yr the corporate established quite a few partnerships to increase entry to its reSET and reSET-O choices geared toward treating substance use and opioid use dysfunction, together with collaborating with the Wisconsin Department of Health Services, Spero Health, and the California Division of Healthcare Companies. The corporate additionally introduced plans to supply its prescription digital therapeutics through telehealth providers.
Dr. Cecil Lynch provides extra particulars throughout the HIMSS23 session “How the Human Genome is Altering Precision Drugs.” It’s scheduled for Wednesday, April 19 at 11:30 a.m. – 12:30 p.m. CT at South Constructing, Degree 4, room S406 A.
Editor’s word: This story has been up to date with further info from a submitting with the Securities and Change Fee.
Pear Therapeutics, maker of prescription digital therapeutics, introduced in the present day that it has filed for Chapter 11 chapter and is searching for a sale of its enterprise or property.
The corporate will proceed its scaled-down operations throughout Chapter 11 because it seeks a sale, and Pear will use its accessible money to fund its operations and prices post-petition.
The Boston-based firm’s CEO Corey McCann referenced the filing on LinkedIn, stating, “In the present day is a tough day for Pear Therapeutics. We introduced that Pear voluntarily filed for Chapter 11 and can search to promote property by way of a gross sales course of. We additionally introduced a discount in power, together with me. That is actually not the end result I envisioned after I based Pear in 2013.”
In a submitting with the Securities and Exchange Commission, Pear mentioned it could lay off roughly 170 workers, almost its complete workforce. The corporate would keep a transition group of about 15 workers to proceed operations in reference to Chapter 11.
McCann stepped down as the corporate’s CEO and president. In accordance with the submitting, he’ll proceed to function a board member and supply consulting providers by way of the deliberate sale course of. Christopher D.T. Guiffre, Pear’s chief working officer and chief monetary officer, will function the corporate’s government officer.
By way of LinkedIn, McCann thanked the departing Pear workers and highlighted their accomplishment in bringing a few of the first prescription digital therapeutics to market. He famous market circumstances induced the corporate and different growth-stage companies to face challenges during the last two years.
“Here is to the way forward for digital drugs that we have labored so onerous to create,” McCann mentioned.
THE LARGER TREND
Final month, Pear announced it was exploring “strategic alternatives,” together with a doable firm sale, merger or acquisition. It employed a monetary advisor to look into actions that would “maximize shareholder worth,” together with a possible sale, M&A, divestiture of property, licensing or different strategic transactions.
With no transaction, Pear mentioned the corporate would wish to reorganize, liquidate or pursue different kinds of restructuring. In a filing with the Securities and Exchange Commission, Pear withdrew its income and working steering for fiscal 2022 and 2023. It didn’t maintain a fourth quarter and full-year earnings name.
The publicly-traded firm wasn’t resistant to the various layoffs seen all through the digital well being sector. In November, Pear mentioned it could reduce its workforce by about 59 employees, or round 22% of the corporate. In July, it let go of approximately 25 employees, making up about 9% of its workforce.
Nonetheless, final yr the corporate established quite a few partnerships to increase entry to its reSET and reSET-O choices geared toward treating substance use and opioid use dysfunction, together with collaborating with the Wisconsin Department of Health Services, Spero Health, and the California Division of Healthcare Companies. The corporate additionally introduced plans to supply its prescription digital therapeutics through telehealth providers.
Dr. Cecil Lynch provides extra particulars throughout the HIMSS23 session “How the Human Genome is Altering Precision Drugs.” It’s scheduled for Wednesday, April 19 at 11:30 a.m. – 12:30 p.m. CT at South Constructing, Degree 4, room S406 A.
Editor’s word: This story has been up to date with further info from a submitting with the Securities and Change Fee.
Pear Therapeutics, maker of prescription digital therapeutics, introduced in the present day that it has filed for Chapter 11 chapter and is searching for a sale of its enterprise or property.
The corporate will proceed its scaled-down operations throughout Chapter 11 because it seeks a sale, and Pear will use its accessible money to fund its operations and prices post-petition.
The Boston-based firm’s CEO Corey McCann referenced the filing on LinkedIn, stating, “In the present day is a tough day for Pear Therapeutics. We introduced that Pear voluntarily filed for Chapter 11 and can search to promote property by way of a gross sales course of. We additionally introduced a discount in power, together with me. That is actually not the end result I envisioned after I based Pear in 2013.”
In a submitting with the Securities and Exchange Commission, Pear mentioned it could lay off roughly 170 workers, almost its complete workforce. The corporate would keep a transition group of about 15 workers to proceed operations in reference to Chapter 11.
McCann stepped down as the corporate’s CEO and president. In accordance with the submitting, he’ll proceed to function a board member and supply consulting providers by way of the deliberate sale course of. Christopher D.T. Guiffre, Pear’s chief working officer and chief monetary officer, will function the corporate’s government officer.
By way of LinkedIn, McCann thanked the departing Pear workers and highlighted their accomplishment in bringing a few of the first prescription digital therapeutics to market. He famous market circumstances induced the corporate and different growth-stage companies to face challenges during the last two years.
“Here is to the way forward for digital drugs that we have labored so onerous to create,” McCann mentioned.
THE LARGER TREND
Final month, Pear announced it was exploring “strategic alternatives,” together with a doable firm sale, merger or acquisition. It employed a monetary advisor to look into actions that would “maximize shareholder worth,” together with a possible sale, M&A, divestiture of property, licensing or different strategic transactions.
With no transaction, Pear mentioned the corporate would wish to reorganize, liquidate or pursue different kinds of restructuring. In a filing with the Securities and Exchange Commission, Pear withdrew its income and working steering for fiscal 2022 and 2023. It didn’t maintain a fourth quarter and full-year earnings name.
The publicly-traded firm wasn’t resistant to the various layoffs seen all through the digital well being sector. In November, Pear mentioned it could reduce its workforce by about 59 employees, or round 22% of the corporate. In July, it let go of approximately 25 employees, making up about 9% of its workforce.
Nonetheless, final yr the corporate established quite a few partnerships to increase entry to its reSET and reSET-O choices geared toward treating substance use and opioid use dysfunction, together with collaborating with the Wisconsin Department of Health Services, Spero Health, and the California Division of Healthcare Companies. The corporate additionally introduced plans to supply its prescription digital therapeutics through telehealth providers.
Dr. Cecil Lynch provides extra particulars throughout the HIMSS23 session “How the Human Genome is Altering Precision Drugs.” It’s scheduled for Wednesday, April 19 at 11:30 a.m. – 12:30 p.m. CT at South Constructing, Degree 4, room S406 A.
